Soberana Plus
Soberana Plus is a COVID-19 vaccine developed by the Finlay Institute in Cuba. It is part of the Soberana vaccine family, which includes Soberana 01 and Soberana 02. Soberana Plus is designed as a booster dose to enhance the immune response in individuals who have previously been vaccinated with other COVID-19 vaccines or have recovered from a COVID-19 infection.
Development[edit | edit source]
The development of Soberana Plus began in response to the global COVID-19 pandemic. The Finlay Institute, a leading Cuban biomedical research organization, spearheaded the project. The vaccine is based on a recombinant protein subunit platform, which uses a part of the SARS-CoV-2 virus to stimulate an immune response without causing the disease.
Clinical Trials[edit | edit source]
Soberana Plus underwent several phases of clinical trials to evaluate its safety and efficacy. The trials included participants who had previously received other COVID-19 vaccines or had recovered from COVID-19. The results indicated that Soberana Plus significantly boosted the immune response, providing enhanced protection against the virus.
Approval and Distribution[edit | edit source]
The Cuban regulatory authorities granted emergency use authorization for Soberana Plus after reviewing the clinical trial data. The vaccine has been distributed within Cuba and to several other countries as part of international cooperation efforts. The distribution strategy focuses on using Soberana Plus as a booster dose to complement other vaccination programs.
Mechanism of Action[edit | edit source]
Soberana Plus works by introducing a recombinant protein subunit of the SARS-CoV-2 virus into the body. This protein is recognized by the immune system, which then produces antibodies and activates T-cells to fight the virus. The booster dose enhances the immune memory, providing longer-lasting protection against COVID-19.
Efficacy[edit | edit source]
Studies have shown that Soberana Plus is effective in boosting the immune response in individuals who have been previously vaccinated or have recovered from COVID-19. The vaccine has demonstrated a good safety profile with minimal side effects.
See Also[edit | edit source]
References[edit | edit source]
External Links[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
